Last reviewed · How we verify
Olanzapine and Amisulpride
This is a combination of two atypical antipsychotics that block dopamine and serotonin receptors to reduce psychotic symptoms and stabilize mood.
This is a combination of two atypical antipsychotics that block dopamine and serotonin receptors to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar disorder.
At a glance
| Generic name | Olanzapine and Amisulpride |
|---|---|
| Also known as | Zyprexa, Amisuprid Hexal |
| Sponsor | Heinrich-Heine University, Duesseldorf |
| Drug class | Atypical antipsychotic combination |
| Target | Dopamine D2 receptor, Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Olanzapine is a thienobenzodiazepine that antagonizes dopamine D2 and serotonin 5-HT2A receptors, while amisulpride is a benzamide that selectively blocks dopamine D2/D3 receptors, particularly at mesolimbic and mesocortical pathways. Together, they provide complementary antipsychotic and mood-stabilizing effects through overlapping but distinct receptor profiles.
Approved indications
- Schizophrenia
- Bipolar disorder
Common side effects
- Weight gain
- Sedation
- Extrapyramidal symptoms
- Metabolic syndrome
- Prolactin elevation
Key clinical trials
- Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT) (PHASE3)
- Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in Post-Schizophrenic Depression (PHASE4)
- Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental Disorders (NA)
- Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis (PHASE2)
- Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients
- Amisulpride Treatment for BPSD in AD Patients (NA)
- Prolactin Change in Chinese Patients With Schizophrenia After Antipsychotics Treatment
- Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Olanzapine and Amisulpride CI brief — competitive landscape report
- Olanzapine and Amisulpride updates RSS · CI watch RSS
- Heinrich-Heine University, Duesseldorf portfolio CI